No abstract

Botulinum toxin A injection of the laryngeal hyperfunctional muscles has been found over the past 12 years to be the treatment of choice to control the dystonic symptoms in most patients with spasmodic dysphonia.

The purpose of this study is to determine if subjects in the early stages of untreated Parkinson's disease (PD) or PD treated with deprenyl alone suffer from motor speech abnormalities. Speech defects are common in advanced PD, including disturbances of respiration, phonation, and articulation. We studied 12 subjects with early PD (Hoehn and Yahr stage < or = 2, mean duration disease 3.2 years) who were not taking symptomatic therapy and tested them under two conditions: on and off deprenyl. None of the subjects was depressed or demented (Mini Mental Status mean 29.9/30; Hamilton Depression Rating mean 2.7/52). All functioned independently (Schwab and England Activities of Daily Living mean 93.1/100). Acoustic and speech productions were assessed using the DSP Sona-Graph 5500 and an evaluation of dysarthria. All 12 had at least two characteristics of dysarthria on examination, although 8 were not aware of it. Vocal tremor was identified on narrow band spectrogram for four subjects. Deprenyl did not have a consistent effect on speech. Ten subjects had no detectable change in speech on deprenyl, one was worse, and one was improved.

Primary or secondary tracheoesophageal puncture with a speaking prosthesis has provided rehabilitation of speech in most patients after total laryngectomy. Persistent constrictor spasm is thought to be responsible for a small percentage of these patients' inability to speak with the prosthesis. Management of these patients has included bougienage and pharyngeal myotomy and/or pharyngeal neurectomy. Botulinum toxin injections of the cricopharyngeus muscle complex in six patients have been successfully used diagnostically and therapeutically for tracheoesophageal puncture failures. The assessment, technique, and results are discussed.

No abstract

Stuttering is an action-induced speech disorder with involuntary, audible, or silent repetitions or prolongations in the utterance of short speech elements (sounds, syllables) and words. Symptomatic treatment programs frequently have initial success; persistent benefit is variable and many patients remain disabled. Stuttering has many characteristics similar to spasmodic dysphonia (laryngeal dystonia), often including the presence of adductor laryngeal spasms that obstruct airflow (glottal block). We hypothesized that relief of the spasmodic dysphonic glottal blocks in stutterers would modify the stuttering phenomenon and increase fluency. We therefore studied the effects of bilateral vocal fold injections of botulinum toxin type A (BTX) on dysfluency and speech characteristics in stuttering. We treated 14 adult patients (12 men, 2 women) with persistent stuttering and glottal block who previously failed standard speech therapy with 1.25 U BTX into each thyroarytenoid (vocalis) muscle. Fluency evaluations included the Stuttering Severity Instrument, the Perceptions of Stuttering Inventory, and a global rating scale (percent of normal function). Patients were evaluated at baseline and at 2-, 6-, and 12-week follow-up visits. Improvement in fluency documented by each rating instrument occurred at 2 and 6 weeks, with functional relapse by 12 weeks in most patients. We conclude that therapeutic laryngeal injections of botulinum toxin are useful in the management of stuttering with glottal block and result in a moderate improvement in fluency. When an adult patient with developmental stuttering with glottal blocks has failed speech interventional therapy and presents for treatment, a trial of BTX can be considered early.(ABSTRACT TRUNCATED AT 250 WORDS)

No abstract

ReferencesDanek A. Geniospasm: hereditary chin trembling. Mov Disord 1993;8:335-8. Laurance BM, Matthews WB, Diggle JH. Hereditary quivering of the chin. Arch Dis Child 1968;43:249-51. Alsager DE, Bowen P, Bamforth JS. Trembling chin-a report of this inheritable dominant character in a fourgeneration Canadian family. Clin Genet 1991 ;40: 186-9. Gordon K, Cadera W, Hinton G . Successful treatment of hereditary trembling chin with botulinum toxin. J Child Neurol 1993;8: 154-6. Grossman BJ. Trembling of the chin: an inheritable dominant character. Pediatrics 1957; 19:453-5. Johnson LF, Kinsbourne M, Renuart AW. Hereditary chintrembling with nocturnal myoclonus and tongue-biting in dizygous twins. Dev Med Child Neurol 1971;13:72&9. Wadlington WB. Familial trembling of the chin. J Pediatr 19% ;53 : 3 162 1. Rosenberg ML, Clark JB. Familial trembling of the chin. Neurology 1987;37(suppl 1 ) : 190. Blaw ME, Leroy RF, Steinberg JB, Herman J. Hereditary quivering chin and REM behavioral disorder. Ann Neurol 1989;26:471. Stocks P. Facial spasm inherited through four generations. Biometrika 1922123; 14:3 1 1-5. Goldsmith JB. The inheritance of "facial spasm." J Hered 1927; 18: 185-7. Biary N, Koller WC. Essential tongue tremor. Mov Disord 1987;2:25-9. Rapoport A, Lampel Y, Sarova I. Clinical and epidemiological features of essential tremor of the jaw. Mov Disord 1991 ; 6:276. Koller WC, Glatt S, Biary N, Rubino FA. Essential tremor variants: effect of treatment. Clin Neuropharmacol 1987;4: Bain PG, Findley LJ, Thompson PD, et al. A study of hereditary essential tremor. Brain 1994;117:805-34. Jedynak CP, Bonnet AM, Agid Y. Tremor and idiopathic dystonia. Mov Disord 1991 ;6:230-6. Elble RJ, Moody C, Higgins C. Primary writing tremor. A form of focal dystonia? Mov Disord 1990;5: 118-26. Rivest J, Marsden CD. Trunk and head tremor as isolated Videotape segments accompany this article.